Skip to main content
SpringerLink
Log in

Disease Presentation, Recognition and Prevention

  • Chapter
  • First Online:
Cancer and AIDS

  • 261 Accesses

Abstract

The human development index (HDI) correlates with aspects of health, including the level of national healthcare systems (NHCS), and patterns of cancer presentation (CP). Deficiencies in NHCS result in forms of delayed CP, including grotesque mass formations in breast cancer (BC-CfE, British Columbia centre for excellence in HIV/AIDS. What is treatment as prevention? Vancouver, British Columbia, Canada, 2015. Available from: http://www.cfenet.ubc.ca), kidney failure in cervical cancer (CC), or hyperleucocytosis-induced neuropsychiatric syndromes in leukemias. These contrast with the peanut-sized self-discovered breast mass in BC, the shallow cervical ulcer observed on investigation of abnormal genital discharge in early CC, or the investigation of an abnormal blood count discovered on routine annual check-up in early chronic myeloid leukemia, as seen in NHCS of high/very high HDI (H/VH-HDI) countries. Resources and manpower rich status of H/VH-HDI countries enables the establishment of organized national mammographic screening programs for early detection (ED) of BC, and Papanicoulao smears for cytology and human papilloma virus (CliffordGM, Goncalves MAG, Franceschi S, HPV, Group Hs, Human papillomavirus types among women infected with HIV: a meta-analysis. Aids 20(18):2337–2344, 2006) DNA detection for CC, with resultant reduction of mortality. In most countries of medium or low HDI (M/L-HDI), such programs are less feasible compared to the less expensive but less efficacious ones such as clinical breast examination (CBE) for ED of BC, and Visual Inspection with Acetic Acid (VIA) for ED of CC. Primary prevention of virus-associated cancers, such as CC (CliffordGM, Goncalves MAG, Franceschi S, HPV, Group Hs, Human papillomavirus types among women infected with HIV: a meta-analysis. Aids 20(18):2337–2344, 2006) and liver cancer (HBV) has been possible by vaccination since 2006 and the early1980s respectively. Governmental control of tobacco and alcohol use, improved food preservation, and personal obesity management and hygiene are additional cancer prevention methods. Pre-exposure prophylaxis is emerging as HIV/AIDS prevention strategy in lieu of HIV vaccine.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. BC-CfE. British Columbia Centre for Excellence in HIV/AIDS. What is Treatment as Prevention? Vancouver, British Columbia, Canada. 2015. Available from: http://www.cfenet.ubc.ca

  2. Clifford GM, Goncalves MAG, Franceschi S. HPV, group Hs. Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS. 2006;20(18):2337–44.

    Article  PubMed  Google Scholar 

  3. UNDP. United Nations Development Programme. Human Development Report. Geneva, Switzerland: United Nations Development Programme. 2016. Available from: http://www.hdr.undp.org; https://en.wikipedia.org/wiki/List_of_countries_by_Human_Development_Index

  4. Macleod U, Mitchell E, Burgess C, Macdonald S, Ramirez A. Risk factors for delayed presentation and referral of symptomatic cancer: evidence for common cancers. Br J Cancer. 2009;101:S92–S101.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Fruchter R, Boyce J, Hunt M. Invasive cancer of cervix: failures in prevention; I. Previous Pap smear tests and opportunities for screening. N Y State J Med. 1980;80(5):740–5.

    CAS  PubMed  Google Scholar 

  6. Fowler WC, Freeman A, Hulka B, Kaluzny A, O'Keefe S, Symons M, et al. Delays in cervical cancer treatment. Prog Clin Biol Res. 1984;156:265–74.

    PubMed  Google Scholar 

  7. Smith EM, Anderson B. Symptomatology, delay, and stage of disease in endometrial cancer. Cancer Detect Prev. 1986;10(3–4):247–54.

    Google Scholar 

  8. Cochran SD, Hacker NF, Berek J. Correlates of delay in seeking treatment for endometrial cancer. J Psychosom Obstet Gynecol. 1986;5(4):245–52.

    Article  Google Scholar 

  9. Smith EM, Anderson B. The effects of symptoms and delay in seeking diagnosis on stage of disease at diagnosis among women with cancers of the ovary. Cancer. 1985;56(11):2727–32.

    Article  CAS  PubMed  Google Scholar 

  10. Andersen BL, Cacioppo JT, Roberts DC. Delay in seeking a cancer diagnosis: delay stages and psychophysiological comparison processes. Br J Soc Psychol. 1995;34(1):33–52.

    Article  PubMed  Google Scholar 

  11. Coates RJ, Click LA, Harlan LC, Robboy S, Barrett RJ II, Eley JW, et al. Differences between black and white patients with cancer of the uterine corpus in interval from symptom recognition to initial medical consultation (United States). Cancer Causes Control. 1996;7(3):328–36.

    Article  CAS  PubMed  Google Scholar 

  12. United Nations Development Programme. Human development report 1990. Concept and measurement of human development. New York: UNDP; 1990; 1990 Available from: http://hdr.undp.org/en/reports/global/hdr1990/

    Book  Google Scholar 

  13. Franceschi S, La Vecchi C, Gallus G, Decarli A, Colombo E, Mangioni C, et al. Delayed diagnosis of endometrial cancer in Italy. Cancer. 1983;51(6):1176–8.

    Article  CAS  PubMed  Google Scholar 

  14. Howell D, Fitch MI, Deane KA. Women’s experiences with recurrent ovarian cancer. Cancer Nurs. 2003;26(1):10–7.

    Article  PubMed  Google Scholar 

  15. Risberg T, Sørbye S, Norum J, Wist E. Diagnostic delay causes more psychological distress in female than in male cancer patients. Anticancer Res. 1995;16(2):995–9.

    Google Scholar 

  16. Jones R, Joura E. Analyzing prior clinical events at presentation in 102 women with vulvar carcinoma. Evidence of diagnostic delays. J Reprod Med. 1999;44(9):766–8.

    CAS  PubMed  Google Scholar 

  17. Menon R, Sehgal A, Singh V, Murthy N, Luthra U. Medical attention-seeking behaviour of cervical cancer patients. Implication for cervical cancer control in developing countries. Cancer J. 1991;4(3):202–5.

    Google Scholar 

  18. Dhamija S, Sehgal A, Luthra UK, Sehgal K. Factors associated with awareness and knowledge of cervical cancer in a community: implication for health education programmes in developing countries. J R Soc Promot Heal. 1993;113(4):184–6.

    CAS  Google Scholar 

  19. Kidanto H, Kilewo CD, Moshiro C. Cancer of the cervix: knowledge and attitudes of female patients admitted at Muhimbili National Hospital, Dar-es-Salaam. East Afr Med J. 2002;79(9):467–75.

    CAS  PubMed  Google Scholar 

  20. Ajayi I, Adewole IF. Knowledge and attitude of general outpatient attendants in Nigeria to cervical cancer. Cent Afr J Med. 1998;44(2):41–3.

    CAS  PubMed  Google Scholar 

  21. Ramirez A, Westcombe A, Burgess C, Sutton S, Littlejohns P, Richards M. Factors predicting delayed presentation of symptomatic breast cancer: a systematic review. Lancet. 1999;353(9159):1127–31.

    Article  CAS  PubMed  Google Scholar 

  22. Mitchell E, Macdonald S, Campbell N, Weller D, Macleod U. Influences on pre-hospital delay in the diagnosis of colorectal cancer: a systematic review. Br J Cancer. 2008;98(1):60–70.

    Article  CAS  PubMed  Google Scholar 

  23. Månsson Å, Anderson H, Colleen S. Time lag to diagnosis of bladder cancer–influence of psychosocial parameters and level of health-care provision. Scand J Urol Nephrol. 1993;27(3):363–9.

    Article  PubMed  Google Scholar 

  24. Mor V, Masterson-Allen S, Goldberg R, Guadagnoli E, Wool MS. Pre-diagnostic symptom recognition and help seeking among cancer patients. J Community Health. 1990;15(4):253–66.

    Article  CAS  PubMed  Google Scholar 

  25. Group TAS. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;2015(373):808–22.

    Google Scholar 

  26. Hackett TP, Cassem NH, Raker JW. Patient delay in cancer. N Engl J Med. 1973;289(1):14–20.

    Article  CAS  PubMed  Google Scholar 

  27. Worden JW, Weisman AD. Psychosocial components of lagtime in cancer diagnosis. J Psychosom Res. 1975;19(1):69–79.

    Article  CAS  PubMed  Google Scholar 

  28. Bowen EF, Rayner CF. Patient and GP led delays in the recognition of symptoms suggestive of lung cancer. Lung Cancer. 2002;37(2):227–8.

    Article  PubMed  Google Scholar 

  29. Koyi H, Hillerdal G, Brandén E. Patient’s and doctors’ delays in the diagnosis of chest tumors. Lung Cancer. 2002;35(1):53–7.

    Article  PubMed  Google Scholar 

  30. Samet JM, Hunt WC, Lerchen ML, Goodwin JS. Delay in seeking care for cancer symptoms: a population-based study of elderly New Mexicans. J Natl Cancer Inst. 1988;80(6):432–8.

    Article  CAS  PubMed  Google Scholar 

  31. Prout GR, Wesley MN, Greenberg RS, Chen VW, Brown CC, Miller AW, et al. Bladder cancer. Cancer. 2000;89(6):1349–58.

    Article  PubMed  Google Scholar 

  32. Bosl G, Goldman A, Lange P, Vogelzang N, Fraley E, Levitt S, et al. Impact of delay in diagnosis on clinical stage of testicular cancer. Lancet. 1981;318(8253):970–3.

    Article  Google Scholar 

  33. Attard G. Delay in treatment of testicular tumours in the army. J R Army Med Corps. 1985;131(3):140–1.

    Article  CAS  PubMed  Google Scholar 

  34. Ho E, Johnston S, Keane P. The haematuria clinic – referral patterns in Northern Ireland. Ulster Med J. 1998;67(1):25.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Mommsen S, Aagaard J, Sell A. Presenting symptoms, treatment delay and survival in bladder cancer. Scand J Urol Nephrol. 1983;17(2):163–7.

    Article  CAS  PubMed  Google Scholar 

  36. Thornhill J, Fennelly J, Kelly D, Walsh A, Fitzpatrick J. Patients’ delay in the presentation of testis cancer in Ireland. Br J Urol. 1987;59(5):447–51.

    Article  CAS  PubMed  Google Scholar 

  37. Hernes E, Harstad K. Changing incidence and delay of testicular cancer in southern Norway (1981–1992). Eur Urol. 1995;30(3):349–57.

    Article  Google Scholar 

  38. Fitzpatrick P, Corcoran N, Fitzpatrick J. Prostate cancer: how aware is the public? Br J Urol. 1998;82:43–8.

    Article  CAS  PubMed  Google Scholar 

  39. Khadra A, Oakeshott P. Pilot study of testicular cancer awareness and testicular self-examination in men attending two South London general practices. Fam Pract. 2002;19(3):294–6.

    Article  PubMed  Google Scholar 

  40. Gascoigne P, Mason M, Roberts E. Factors affecting presentation and delay in patients with testicular cancer: results of a qualitative study. Psycho-Oncology. 1998;8(2):144–54.

    Article  Google Scholar 

  41. Sandén I, Larsson US, Eriksson C. An interview study of men discovering testicular cancer. Cancer Nurs. 2000;23(4):304–9.

    Article  PubMed  Google Scholar 

  42. De Nooijer J, Lechner L, De Vries H. Help-seeking behaviour for cancer symptoms: perceptions of patients and general practitioners. Psycho-Oncology. 2001;10(6):469–78.

    Article  PubMed  Google Scholar 

  43. Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. Cancer. 2000;89(10):2068–75.

    Article  CAS  PubMed  Google Scholar 

  44. Fitch MI, Deane K, Howell D, Gray RE. Women’s experiences with ovarian cancer: reflections on being diagnosed. Can Oncol Nursing J/Rev Canadienne de Soins Infirmiers Oncol. 2002;12(3):152–9.

    Article  Google Scholar 

  45. Pereira J, Ikari F, Minamoto H, Cassioli J. Delay factors in the diagnosis of lung cancer: a public health problem. Rev Paul Med. 1990;109(3):109–12.

    Google Scholar 

  46. Silva P, Pereira J, Ikari F, Minamoto H. Lung cancer and the delay in the diagnosis: analysis of 300 cases. Rev Assoc Med Bras. 1992). 1991;38(3):145–9.

    CAS  PubMed  Google Scholar 

  47. Macdonald S, Macleod U, Mitchell E, Weller D, Campbell N, Mant D. Factors influencing patient and primary care delay in the diagnosis of cancer: a database of existing research and its implications for future practice. Report to the Department of Health: cancer symptom profiles and referral strategies for the primary care research programme University of Glasgow, Glasgow. 2004

    Google Scholar 

  48. Piot P. Ebola’s perfect storm. Science. 2014;345(6202):1221.

    Article  CAS  PubMed  Google Scholar 

  49. Tabar L, Yen M-F, Vitak B, Chen H-HT, Smith RA, Duffy SW. Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet. 2003;361(9367):1405–10.

    Article  PubMed  Google Scholar 

  50. Gorin SS, Heck JE, Cheng B, Smith SJ. Delays in breast cancer diagnosis and treatment by racial/ethnic group. Arch Intern Med. 2006;166(20):2244–52.

    Article  PubMed  Google Scholar 

  51. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492–502.

    Article  CAS  PubMed  Google Scholar 

  52. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Early breast cancer trialists collaborative group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087–106.

    Article  CAS  PubMed  Google Scholar 

  53. Group EBCTC. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717.

    Article  CAS  Google Scholar 

  54. Vento S. Cancer control in Africa: which priorities? Lancet Oncol. 2013;14(4):277–9.

    Article  PubMed  Google Scholar 

  55. Anyanwu SN. Temporal trends in breast cancer presentation in the third world. J Exp Clin Cancer Res. 2008;27(1):1.

    Article  Google Scholar 

  56. Foster RS Jr, Lang SP, Costanza MC, Worden JK, Haines CR, Yates JW. Breast self-examination practices and breast-cancer stage. N Engl J Med. 1978;299(6):265–70.

    Article  PubMed  Google Scholar 

  57. Duncan W, Kerr G. The curability of breast cancer. BMJ. 1976;2(6039):781–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Baum M. The curability of breast cancer. Br Med J. 1976;1(6007):439.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Brinkley D, Haybittle J. The curability of breast cancer. World J Surg. 1977;1(3):287–9.

    Article  CAS  PubMed  Google Scholar 

  60. Elgaili EM, Abuidris DO, Rahman M, Michalek AM, Mohammed SI. Breast cancer burden in central Sudan. Int J Womens Health. 2010;2:77–82.

    PubMed  PubMed Central  Google Scholar 

  61. Chopra R (ed). Management of locally advanced breast cancer in India. Global Summit Consensus Conference. 2002

    Google Scholar 

  62. Khaled HM. Breast cancer at diagnosis in women of Africa and the Middle East. In: Williams CKO, Olopade OI, Falkson CI, editors. Breast cancer in women of African descent. Dordrecht: Springer; 2006. p. 81–90.

    Chapter  Google Scholar 

  63. Gebremedhin A, Shamebo M. Clinical profile of Ethiopian patients with breast cancer. East Afr Med J. 1998;75(11):640–3.

    CAS  PubMed  Google Scholar 

  64. Adesunkanmi A, Lawal O, Adelusola K, Durosimi M. The severity, outcome and challenges of breast cancer in Nigeria. Breast. 2006;15(3):399–409.

    Article  CAS  PubMed  Google Scholar 

  65. Liedke PE, Finkelstein DM, Szymonifka J, Barrios CH, Chavarri-Guerra Y, Bines J, et al. Outcomes of breast cancer in Brazil related to health care coverage: a retrospective cohort study. Cancer Epidemiol Biomark Prev. 2014;23(1):126–33.

    Article  Google Scholar 

  66. Kingham TP, Alatise OI, Vanderpuye V, Casper C, Abantanga FA, Kamara TB, et al. Treatment of cancer in sub-Saharan Africa. Lancet Oncol. 2013;14(4):e158–e67.

    Article  PubMed  Google Scholar 

  67. Facione NC. Delay versus help seeking for breast cancer symptoms: a critical review of the literature on patient and provider delay. Soc Sci Med. 1993;36(12):1521–34.

    Article  CAS  PubMed  Google Scholar 

  68. Elmore JG, Nakano CY, Linden HM, Reisch LM, Ayanian JZ, Larson EB. Racial inequities in the timing of breast cancer detection, diagnosis, and initiation of treatment. Med Care. 2005;43(2):141–8.

    Article  PubMed  Google Scholar 

  69. Yabroff KR, Breen N, Vernon SW, Meissner HI, Freedman AN, Ballard-Barbash R. What factors are associated with diagnostic follow-up after abnormal mammograms? Findings from a US National Survey. Cancer Epidemiol Biomark Prev. 2004;13(5):723–32.

    Google Scholar 

  70. Dennis CR, Gardner B, Lim B. Analysis of survival and recurrence vs. patient and doctor delay in treatment of breast cancer. Cancer. 1975;35(3):714–20.

    Article  CAS  PubMed  Google Scholar 

  71. Vernon SW, Tilley BC, Neale AV, Steinfeldt L. Ethnicity, survival, and delay in seeking treatment for symptoms of breast cancer. Cancer. 1985;55(7):1563–71.

    Article  CAS  PubMed  Google Scholar 

  72. Khokhar A. Breast cancer in India: where do we stand and where do we go? Asian Pac J Cancer Prev. 2012;13(10):4861–6.

    Article  PubMed  Google Scholar 

  73. Marmot M, Atinmo T, Byers T, Chen J, Hirohata T, Jackson A, et al. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. 2007

    Google Scholar 

  74. Naijanet. Heartless!!! Man Abandons Wife In Hospital Over N520,000 Unpaid Bill. http://mippinappgenerator.com/mip/pct.jsp?p=1135175923_656819&wl=9. September 16, 2016

  75. Cortes JE, Talpaz M, Kantarjian H. Chronic myelogenous leukemia: a review. Am J Med. 1996;100(5):555–70.

    Article  CAS  PubMed  Google Scholar 

  76. Cortes JE, Silver RT, Kantarjian H. Chronic myeloid leukemia. In: Kufe DW, Bast RC, Hait WN, Hong WK, Pollock RE, Weichselbaum RR, et al., editors. Cancer medicine. 6th ed. Hamilton: BC Decker; 2003. p. 1761–71.

    Google Scholar 

  77. Spiers A. The clinical features of chronic granulocytic leukaemia. Clin Haematol. 1977;6(1):77–95.

    CAS  PubMed  Google Scholar 

  78. Tanzer J, Frei E. Chronic myeloid leukemia. In: Holland JF, Frei E, editors. Cancer medicine. Philadelphia: Lea and Febiger; 1982. p. 1446–60.

    Google Scholar 

  79. Williams CK, Ogan O. Chronic myeloid leukemia associated with impairment of hearing. Br Med J (Clin Res Ed). 1985;290(6483):1705.

    Article  CAS  Google Scholar 

  80. Mckee LC Jr, Collins RD. Intravascular leukocyte thrombi and aggregates as a cause of morbidity and mortality in leukemia. Medicine. 1974;53(6):463–78.

    Article  PubMed  Google Scholar 

  81. Dang-Tan T, Franco EL. Diagnosis delays in childhood cancer. Cancer. 2007;110(4):703–13.

    Article  PubMed  Google Scholar 

  82. Donaldson SS, Egbert PR, Newsham I, Cavenee WK. Retinoblastoma. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. Third ed. Philadelphia: Lippincott-Raven; 1997. p. 699–715.

    Google Scholar 

  83. Balmer A, Munier F. Differential diagnosis of leukocoria and strabismus, first presenting signs of retinoblastoma. Clinical ophthalmology (Auckland, NZ). 2007;1(4):431.

    Google Scholar 

  84. Magrath IT. African Burkitt’s lymphoma: history, biology, clinical features, and treatment. J Pediatr Hematol Oncol. 1991;13(2):222–46.

    Article  CAS  Google Scholar 

  85. Meremikwu M, Ehiri J, Nkanga D, Udoh E, Ikpatt O, Alaje E. Socioeconomic constraints to effective management of Burkitt’s lymphoma in south-eastern Nigeria. Tropical Med Int Health. 2005;10(1):92–8.

    Article  CAS  Google Scholar 

  86. Gaynon PS, Angiolillo AL, Franklin JL, Reaman GH. Childhood acute lymphoblastic leukemia. In: Kufe DW, Bast RC, Hait WN, Kong WK, Pollock RE, Weichselbaum RR, et al., editors. Cancer medicine. 7th ed. Hamilton: BC Decker; 2006. p. 1934–43.

    Google Scholar 

  87. Williams CK, Foroni L, Luzzatto L, Saliu I, Levine A, Greaves MF. Childhood leukaemia and lymphoma: African experience supports a role for environmental factors in leukaemogenesis. E Cancer Med Sci. 2014;8:478.

    Google Scholar 

  88. Williams C, Folami A, Laditan A, Ukaejiofo E. Childhood acute leukaemia in a tropical population. Br J Cancer. 1982;46(1):89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Williams CK. Influence of life-style on the pattern of leukaemia and lymphoma subtypes among Nigerians. Leuk Res. 1985;9(6):741–5.

    Article  CAS  PubMed  Google Scholar 

  90. Greaves MF, Colman SM, Beard ME, Bradstock K, Cabrera ME, Chen PM, et al. Geographical distribution of acute lymphoblastic leukaemia subtypes: second report of the collaborative group study. Leukemia. 1993;7(1):27–34.

    CAS  PubMed  Google Scholar 

  91. Williams C. Neoplastic diseases of the haemopoietic system in Ibadan: preliminary report of a prospective study. Afr J Med Sci. 1985;14:89–94.

    CAS  Google Scholar 

  92. Carneiro IA, Drakeley CJ, Owusu-Agyei S, Mmbando B, Chandramohan D. Haemoglobin and haematocrit: is the threefold conversion valid for assessing anaemia in malaria-endemic settings? Malar J. 2007;6(1):1.

    Article  CAS  Google Scholar 

  93. Williams CKO. Clinical manifestation of lymphoid leukaemias in Ibadan. Nig Med J. 1986;16(5–6):51–6.

    Google Scholar 

  94. Margolis JF, Poplack DG. Acute lymphoblastic leukemia. Pizzo PA, Poplack DG, Principles and practice of pediatric oncology. Third Philadelphia: Lippincott-Raven Publishers; 1997. 245

    Google Scholar 

  95. Magrath IT, Shad A, Epelman S, De Camargo B, Petrilli AS, Gad-el-Mawla N, et al. Pediatric oncology in countries with limited resources. 3rd ed. Philadelphia: Lippincott-Raven; 1997.

    Google Scholar 

  96. Aplenc R, Lange B. Acute myeloid leukemia in children. In: Kufe DW, Bast RC, Hait WN, Kong WK, Pollock RE, Weichselbaum RR, et al., editors. Cancer medicine. 7th ed. Hamilton: BC Decker; 2006. p. 1944–50.

    Google Scholar 

  97. Macdougall LG, Jankowitz P, Cohn R, Bernstein R. Acute childhood leukemia in Johannesburg: ethnic differences in incidence, cell type, and survival. J Pediatr Hematol Oncol. 1986;8(1):43.

    Article  CAS  Google Scholar 

  98. Çavdar AO, Gözdaşoǧglu S, Arcasoy A, Demiraǧ B. Chlorama-like ocular manifestations in Turkish children with acute myelomonocytic leukaemia. Lancet. 1971;297(7701):680–2.

    Article  Google Scholar 

  99. Ismail A. The ocular manifestations of chloromas. Bull Ophthalmol Soc Egypt. 1967;60(64):237.

    CAS  PubMed  Google Scholar 

  100. O'Conor G, Davies J. Malignant tumors in African children: with special reference to malignant lymphoma. J Pediatr. 1960;56(4):526–35.

    Article  CAS  PubMed  Google Scholar 

  101. Birch JM, Marsden HB, Swindell R. Incidence of malignant disease in childhood: a 24-year review of the Manchester children’s tumour registry data. Br J Cancer. 1980;42(2):215.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Young J Jr, Miller RW. Incidence of malignant tumors in US children. J Pediatr. 1975;86(2):254.

    Article  PubMed  Google Scholar 

  103. Anderson BO, Braun S, Lim S, Smith RA, Taplin S, Thomas DB. Early detection of breast cancer in countries with limited resources. Breast J. 2003;9(s2):S51–S9.

    Article  PubMed  Google Scholar 

  104. Gómez I, Warnakulasuriya S, Varela-Centelles P, López-Jornet P, Suárez-Cunqueiro M, Diz-Dios P, et al. Is early diagnosis of oral cancer a feasible objective? Who is to blame for diagnostic delay? Oral Dis. 2010;16(4):333–42.

    Article  PubMed  Google Scholar 

  105. Peacock ZS, Pogrel MA, Schmidt BL. Exploring the reasons for delay in treatment of oral cancer. J Am Dent Assoc. 2008;139(10):1346–52.

    Article  PubMed  Google Scholar 

  106. von Karsa L, Dean PB, Arrosi S, Sankaranayanranan R. Screening – principles. In: Stewart BW, Wild C, editors. World cancer report 2014. Lyon: International Agency for Research on Cancer; 2014. p. 322–9.

    Google Scholar 

  107. WHO. World health organization – cancer control: knowledge into action: WHO guide for effective programmes. Geneva: World Health Organization; 2007.

    Google Scholar 

  108. Konig HJ. Eramus University Rotterdam inaugural address. Rotterdam: Eramus University; 2011.

    Google Scholar 

  109. Smith RA. Expert Group: IARC Handbooks of Cancer Prevention, Breast Cancer Screening, vol. 7. Lyon, France: IARC; 2002. 248pp. Breast Cancer Research. 2003;5(4):1

    Google Scholar 

  110. IARC. IARC Handbooks of Cancer Prevention, Cervix cancer screening, vol. 10. Lyon: International Agency for Cancer Research; 2005.

    Google Scholar 

  111. von Karsa L, Patnick J, Segnan N, Atkin W, Halloran S, Lansdorp-Vogelaar I, et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy. 2013;45(01):51–9.

    Google Scholar 

  112. Wilson JMG, Jungner G. Principles and practice of screening for disease. World Health Organization Public Health Paper (34). 1968

    Google Scholar 

  113. Karsa L, Lignini T, Patnick J, Lambert R, Sauvaget C. The dimensions of the CRC problem. Best Pract Res Clin Gastroenterol. 2010;24(4):381–96.

    Article  CAS  PubMed  Google Scholar 

  114. Vaccarella S, Lortet-Tieulent J, Plummer M, Franceschi S, Bray F. Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors. Eur J Cancer. 2013;49(15):3262–73.

    Article  PubMed  Google Scholar 

  115. Levin TR, Corley DA. Colorectal-cancer screening—coming of age. N Engl J Med. 2013;369(12):1164–6.

    Article  CAS  PubMed  Google Scholar 

  116. von Karsa L. Mammography screening - comprehensive, population-based quality assurance is required (in German). Z Allgemeinmed. 1995;71:1863–7.

    Google Scholar 

  117. WHO. World Health Organization. Executive summary. In: National cancer control programmes: policies and managerial guidelines. Geneva: World Health Organization; 2002.

    Google Scholar 

  118. Zapka JG, Taplin SH, Solberg LI, Manos MM. A framework for improving the quality of cancer care: the case of breast and cervical cancer screening. Cancer Epidemiol Biomark Prev. 2003;12(1):4–13.

    Google Scholar 

  119. Thomas DB, Gao DL, Ray RM, Wang WW, Allison CJ, Chen FL, et al. Randomized trial of breast self-examination in Shanghai: final results. J Natl Cancer Inst. 2002;94(19):1445–57.

    Article  PubMed  Google Scholar 

  120. Semiglazov V, Moiseyenko V, Manikhas A, Protsenko S, Kharikova R, Ivanov V, et al. Role of breast self-examination in early detection of breast cancer: Russia/WHO prospective randomized trial in St. Petersburg Cancer Strategy. 1999;1:145–51.

    Google Scholar 

  121. IARC. IARC working group on the evaluation of cancer-preventive strategies. Breast cancer screening, vol. 7. Lyon: International Agency for Cancer Research; 2002.

    Google Scholar 

  122. Weiss NS. Breast cancer mortality in relation to clinical breast examination and breast self-examination. Breast J. 2003;9(s2):S86–S9.

    Article  PubMed  Google Scholar 

  123. Albert US, Schulz KD. Clinical breast examination: what can be recommended for its use to detect breast cancer in countries with limited resources? Breast J. 2003;9(s2):S90–S3.

    Article  PubMed  Google Scholar 

  124. Ngoma T, Mandeli J, Holland JF. Downstaging cancer in rural Africa. Int J Cancer. 2015;136(12):2875–9.

    Article  CAS  PubMed  Google Scholar 

  125. Mittra I, Mishra GA, Singh S, Aranke S, Notani P, Badwe R, et al. A cluster randomized, controlled trial of breast and cervix cancer screening in Mumbai, India: methodology and interim results after three rounds of screening. Int J Cancer. 2010;126(4):976–84.

    CAS  PubMed  Google Scholar 

  126. De Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13(6):607–15.

    Article  PubMed  Google Scholar 

  127. Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011;12(7):663–72.

    Article  PubMed  PubMed Central  Google Scholar 

  128. Julius JM, Ramondeta L, Tipton KA, Lal LS, Schneider K, Smith JA. Clinical perspectives on the role of the human papillomavirus vaccine in the prevention of cancer. Pharmacother: J Human Pharmacol Drug Ther. 2011;31(3):280–97.

    Article  Google Scholar 

  129. Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki HA, et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One. 2013;8(7):e68329.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  130. AACR. AACR Cancer Progress Report. Making research count for patients: a continual pursuit. Prevention and early detection. Clin Cancer Res: Off J Am Assoc Cancer Res. 2013. 2013;19(Supplement 1):S28–44.

    Google Scholar 

  131. Perry N, Broeders M, De Wolf C, Törnberg S, Holland R, Von Karsa L. European guidelines for quality assurance in breast cancer screening and diagnosis. — summary document. Ann Oncol. 2008;19(4):614–22.

    Article  CAS  PubMed  Google Scholar 

  132. Segnan N, Patnick J, Von Karsa L. European guidelines for quality assurance in colorectal cancer screening and diagnosis: Office for Official Publications of the European Communities. 2010

    Google Scholar 

  133. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, et al. HPV screening for cervical cancer in rural India. N Engl J Med. 2009;360(14):1385–94.

    Article  CAS  PubMed  Google Scholar 

  134. Yang BH, Bray FI, Parkin DM, Sellors JW, Zhang ZF. Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost. Int J Cancer. 2004;109(3):418–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  135. Chen F, Trapido EJ, Davis K. Differences in stage at presentation of breast and gynecologic cancers among whites, blacks, and Hispanics. Cancer. 1994;73(11):2838–42.

    Article  CAS  PubMed  Google Scholar 

  136. Lindau ST, Tomori C, Lyons T, Langseth L, Bennett CL, Garcia P. The association of health literacy with cervical cancer prevention knowledge and health behaviors in a multiethnic cohort of women. Am J Obstet Gynecol. 2002;186(5):938–43.

    Article  PubMed  Google Scholar 

  137. Wright KO, Kuyinu Y, Faduyile F. Community education on cervical cancer amongst market women in an urban area of Lagos. Nigeria Asian Pac J Cancer Prev. 2010;11(1):137–40.

    PubMed  Google Scholar 

  138. Mbamara SU, Ikpeze OC, Okonkwo JE, Onyiaorah IV, Ukah CO. Knowledge, attitude and practice of cervical cancer screening among women attending gynecology clinics in a tertiary level medical care center in southeastern Nigeria. J Reprod Med. 2011;56(11):491.

    PubMed  Google Scholar 

  139. Sauvaget C, Fayette J-M, Muwonge R, Wesley R, Sankaranarayanan R. Accuracy of visual inspection with acetic acid for cervical cancer screening. Int J Gynecol Obstet. 2011;113(1):14–24.

    Article  Google Scholar 

  140. Denny L, Kuhn L, Hu C-C, Tsai W-Y, Wright TC. Human papillomavirus–based cervical cancer prevention: long-term results of a randomized screening trial. J Natl Cancer Inst. 2010;

    Google Scholar 

  141. Y-l Q, Sellors JW, Eder PS, Bao Y-p, Lim JM, F-h Z, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol. 2008;9(10):929–36.

    Article  Google Scholar 

  142. Santesso N, Schünemann H, Blumenthal P, De Vuyst H, Gage J, Garcia F, et al. World Health Organization Guidelines: Use of cryotherapy for cervical intraepithelial neoplasia. Int J Gynecol Obstet. 2012;118(2):97–102.

    Article  Google Scholar 

  143. Williams CK, Stefan DC, Rawlinson F, Simbiri K, Mbulaiteye SM. The African Organisation for Research and Training In Cancer and its conferences: a historical perspective and highlights of the Ninth International Conference, Durban, South Africa, 21–24 November 2013. E Cancer Med Sci. 2014;8

    Google Scholar 

  144. Dinshaw K, Rao D, Ganesh B. Tata memorial hospital cancer registry annual report. Mumbai, India 52. 1999

    Google Scholar 

  145. Yeole B, Jussawalla D, Sabnis S, Sunny L, Sankaranarayanan R, Black R, et al. Survival from breast and cervical cancer in Mumbai (Bombay), India. IARC Sci Publ. 1998:79–88.

    Google Scholar 

  146. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.

    Article  PubMed  Google Scholar 

  147. Sankaranarayanan R, Ramadas K, Thara S, Muwonge R, Prabhakar J, Augustine P, et al. Clinical breast examination: preliminary results from a cluster randomized controlled trial in India. J Natl Cancer Inst. 2011;

    Google Scholar 

  148. Arrieta M-C, Stiemsma LT, Dimitriu PA, Thorson L, Russell S, Yurist-Doutsch S, et al. Early infancy microbial and metabolic alterations affect risk of childhood asthma. Sci Transl Med. 2015;7(307):307ra152.

    Article  PubMed  CAS  Google Scholar 

  149. Schiller JT, Lowy DR. Virus infection and human cancer: an overview. Viruses and human cancer. New York: Springer; 2014. p. 1–10.

    Book  Google Scholar 

  150. Bailey HH, Chuang LT, Eng C, Foxhall LE, Merrill JK, Wollins DS, et al. American society of clinical oncology statement: human papillomavirus caccination for cancer prevention. J Clin Oncol. 2016;34:1803. JCO672014

    Article  CAS  PubMed  Google Scholar 

  151. Kim MN, Han K-H, Ahn SH, editors. Prevention of hepatocellular carcinoma: beyond hepatitis B vaccination. Semin Oncol. 2015;42:316. Elsevier

    Google Scholar 

  152. Herrero R, Franceschi S. Vaccination. In: Stewart BW, Wild C, editors. World cancer report 2014. Lyon: International Agency for Cancer Research; 2014. p. 314–21.

    Google Scholar 

  153. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29(32):4294–301.

    Article  PubMed  PubMed Central  Google Scholar 

  154. Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer. 2008;113(S10):3036–46.

    Article  PubMed  Google Scholar 

  155. CDC. Centers for Disease Control. Prevention prevention of genital HPV infection and sequelae: report of an external consultants’ meeting. Atlanta: Centers for Disease Control and Prevention; 1999.

    Google Scholar 

  156. Agosti JM, Goldie SJ. Introducing HPV vaccine in developing countries—key challenges and issues. N Engl J Med. 2007;356(19):1908–10.

    Article  CAS  PubMed  Google Scholar 

  157. Moscicki A-B, Schiffman M, Burchell A, Albero G, Giuliano AR, Goodman MT, et al. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine. 2012;30:F24–33.

    Article  PubMed  PubMed Central  Google Scholar 

  158. Westra TA, Rozenbaum MH, Rogoza RM, Nijman HW, Daemen T, Postma MJ, et al. Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses. J Infect Dis. 2011;204(3):377–84.

    Article  PubMed  Google Scholar 

  159. Pagliusi SR, Aguado MT. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine. 2004;23(5):569–78.

    Article  PubMed  Google Scholar 

  160. WHO. World Health Organization: new WHO guide to prevent and control cervical cancer: World Health Organization. 2014. Available from: http://www.who.int/mediacentre/news/releases/2014/preventing-cervical-cancer/en/

  161. Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al. Quadruvalent human papillomavirus vaccination: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2014;63(RR-05):1–30.

    PubMed  Google Scholar 

  162. CDC. Centers for disease control prevention recommendations on the use of quadrivalent human papillomavirus vaccine in males – advisory committee on immunization practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011;60(50):1705.

    Google Scholar 

  163. WHO. Comprehensive cervical cancer control. A guide to essential practice. 2nd ed. Geneva: World Health Organization; 2014.

    Google Scholar 

  164. CDC. Center for disease control and prevention. Human papillomavirus vaccination coverage among adolescent girls, 2007–2012, and postlicensure vaccine safety monitoring, 2006–2013-United States. MMWR Morb Mortal Wkly Rep. 2013;62(29):591.

    Google Scholar 

  165. CDC. Center for disease control and prevention. National and state vaccination coverage among adolescents aged 13 through 17 years – United States, 2010. MMWR Morb Mortal Wkly Rep. 2011;60(33):1117.

    Google Scholar 

  166. Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010. J Infect Dis. 2013;208:385. jit192

    Article  CAS  PubMed  Google Scholar 

  167. Schiffman M. The future of cervical screening in the vaccine era. Annual Meeting of the American Society of Clinical Oncology Chicago. 2016

    Google Scholar 

  168. Parkin DM, Bray F. The burden of HPV-related cancers. Vaccine. 2006;24:S11–25.

    Article  Google Scholar 

  169. Bharadwaj M, Hussain S, Nasare V, Das BC. HPV & HPV vaccination: issues in developing countries. 2009

    Google Scholar 

  170. Trottier H, Burchell AN. Epidemiology of mucosal human papillomavirus infection and associated diseases. Public Health Genomics. 2009;12(5–6):291–307.

    Article  PubMed  Google Scholar 

  171. Tindle R, Frazer I. Immune response to human papillomaviruses and the prospects for human papillomavirus-specific immunisation. Human pathogenic papillomaviruses. Heidelberg: Springer; 1994. p. 217–53.

    Google Scholar 

  172. Sankaranarayanan R. Recent advances in prevention research: global cancer prevention. Annual conference of the American Association for Cancer Research. New Orleans. 2016

    Google Scholar 

  173. Dorji T, Tshomo U, Phuntsho S, Tamang TD, Tshokey T, Baussano I, et al. Introduction of a National HPV vaccination program into Bhutan. Vaccine. 2015;33(31):3726–30.

    Article  PubMed  Google Scholar 

  174. Dorji T, Tshomo U. Early implementation and monitoring of HPV vaccination in Bhutan. In: Stewart BW, Wild C, editors. World Cancer Report 2014. Lyon: International Agency for Research on Cancer; 2014. p. 317.

    Google Scholar 

  175. Wong LP. Young multiethnic women's attitudes toward the HPV vaccine and HPV vaccination. Int J Gynecol Obstet. 2008;103(2):131–5.

    Article  Google Scholar 

  176. Binagwaho A, Gatera M, Ngabo F. Introduction and monitoring of a national HPV vacciation programme in Rwanda. In: Stewart BW, Wild C, editors. World cancer report 2014. Lyon: International Agency for Research on Cancer; 2014. p. 318.

    Google Scholar 

  177. WHO. WHO/UNICEF vaccine coverage estimates for 1980–2005. Countries having introduced HepB vaccine and infant HepB3 coverage. 2005. Geneva: World Health Organization. 2006

    Google Scholar 

  178. CDC. Centers for disease control and prevention: viral hepatitis: Hepatitis B information-FAQ for the public. 2016

    Google Scholar 

  179. WHO. World Health Organization hepatitis B fact sheet. 2016. http://www.who.int/mediacentre/factsheets/fs204/en/. World Health Organization

  180. Komatsu H. Hepatitis B virus: where do we stand and what is the next step for eradication. World J Gastroenterol. 2014;20(27):8998–9016.

    PubMed  PubMed Central  Google Scholar 

  181. Trépo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384(9959):2053–63.

    Article  PubMed  CAS  Google Scholar 

  182. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.

    Article  CAS  PubMed  Google Scholar 

  183. Kane MA. Global implementation of human papillomavirus (HPV) vaccine: lessons from hepatitis B vaccine. Gynecol Oncol. 2010;117(2):S32–S5.

    Article  PubMed  Google Scholar 

  184. GAVI. GAVI alliance: delivering on the promise. 2016. http://www.gavi.org/Library/Publications/Pledging-conference-for-immunisation/Delivering-on-the-promise/

  185. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048–56.

    Article  PubMed  CAS  Google Scholar 

  186. Chen D-S, Hsu NH-M, Sung J-L, Hsu T-C, Hsu S-T, Kuo Y-T, et al. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen—carrier mothers. JAMA. 1987;257(19):2597–603.

    Article  CAS  PubMed  Google Scholar 

  187. Chien Y-C, Jan C-F, Kuo H-S, Chen C-J. Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched. Epidemiol Rev. 2006;28(1):126–35.

    Article  PubMed  Google Scholar 

  188. Chang M-H, You S-L, Chen C-J, Liu C-J, Lee C-M, Lin S-M, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst. 2009;101(19):1348–55.

    Article  CAS  PubMed  Google Scholar 

  189. Hadler SC, Fuqiang C, Averhoff F, Taylor T, Fuzhen W, Li L, et al. The impact of hepatitis B vaccine in China and in the China GAVI Project. Vaccine. 2013;31:J66–72.

    Article  PubMed  Google Scholar 

  190. Colditz GA, Wei EK. Preventability of cancer: the relative contributions of biologic and social and physical environmental determinants of cancer mortality. Annu Rev Public Health. 2012;33:137.

    Article  PubMed  PubMed Central  Google Scholar 

  191. US-DOH-HS. US department of health and human services. Women and smoking: a report of the Surgeon General. Rockville: US Department of Health and Human Services, Public Health Service, Office of the Surgeon General; 2001.

    Google Scholar 

  192. CDC. Centers for Disease Control. Prevention how tobacco smoke causes disease: the biology and behavioral basis for smoking-attributable disease: a report of the surgeon general: Centers for Disease Control and Prevention (US). 2010

    Google Scholar 

  193. Borland R, Leon ME. Changing behaviours – tobacco control. In: Stewart B, Wild CP, editors. World cancer report 2014. Lyon: International Agency for Research on Cancer; 2016.

    Google Scholar 

  194. IARC International Agency for Research on Cancer. Reversal of risk after quitting smoking. International Agency for Research on Cancer. 2007

    Google Scholar 

  195. Wellmann K. Smoking and health. on the report of the advisory committee to the surgeon general of the public health service. Dtsch Med Wochenschr. 1946). 1964;89:1085–6.

    Google Scholar 

  196. CDC. Trends in current cigarette smoking among high school students and adults, United States, 1965–2014. Atlanta: Center for Disease Control and Prevention; 2016. Available from: http://www.cdc.gov/tobacco/data_statistics/tables/trends/cig_smoking/

    Google Scholar 

  197. Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, et al. Carcinogenicity of alcoholic beverages. Lancet Oncol. 2007;8(4):292–3.

    Article  PubMed  Google Scholar 

  198. Jha P, Ramasundarahettige C, Landsman V, Rostron B, Thun M, Anderson RN, et al. 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med. 2013;368(4):341–50.

    Article  CAS  PubMed  Google Scholar 

  199. Thun MJ, Carter BD, Feskanich D, Freedman ND, Prentice R, Lopez AD, et al. 50-year trends in smoking-related mortality in the United States. N Engl J Med. 2013;368(4):351–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  200. WHO. WHO (2003) WHO framework convention on tobacco control. Geneva: World Health Organization. Available at: http://www.who.int/fctc/en/index.html; 2003.

    Google Scholar 

  201. WHO. WHO. WHO report on the global tobacco epidemic, 2008: The MPOWER Package. Geneva: WHO; 2008. 2008

    Google Scholar 

  202. IARC. IARC. IARC handbooks of cancer prevention, Tobacco Control: Effectiveness of Tax and Price Policies for tobacco control, vol. 14. Lyon: IARC; 2011. 2011

    Google Scholar 

  203. WHO. WHO. WHO report on the global tobacco epidemic, 2013: enforcing bans on tobacco advertising, promotion and sponsorship. Geneva: WHO. Available at: http://apps.who.int/iris/bitstream/10665/85380/1/9789241505871_eng.pdf; 2013. 2013

    Google Scholar 

  204. WHO. WHO. WHO technical manual on tobacco tax administration. Geneva: WHO. Available at: http://www.who.int/tocacco/publication/tax_administration/en/; 2010. 2010

    Google Scholar 

  205. Levy DT, Benjakul S, Ross H, Ritthiphakdee B. The role of tobacco control policies in reducing smoking and deaths in a middle income nation: results from the Thailand SimSmoke simulation model. Tob Control. 2008;17(1):53–9.

    Article  CAS  PubMed  Google Scholar 

  206. Anonymous. World cancer research fund. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, DC: American Institute for Cancer Research; 2007.

    Google Scholar 

  207. Caballero B. A nutrition paradox—underweight and obesity in developing countries. N Engl J Med. 2005;352(15):1514–6.

    Article  CAS  PubMed  Google Scholar 

  208. Popkin BM, Adair LS, Ng SW. Global nutrition transition and the pandemic of obesity in developing countries. Nutr Rev. 2012;70(1):3–21.

    Article  PubMed  Google Scholar 

  209. Yang CS. Research on esophageal cancer in China: a review. Cancer Res. 1980;40(8 Part 1):2633–44.

    CAS  PubMed  Google Scholar 

  210. Gao YT, McLaughlin JK, Blot WJ, Ji BT, Benichou J, Dai Q, et al. Risk factors for esophageal cancer in Shanghai, China. I. Role of cigarette smoking and alcohol drinking. Int J Cancer. 1994;58(2):192–6.

    Article  CAS  PubMed  Google Scholar 

  211. Ahn J, Chen CY, Hayes RB. Oral microbiome and oral and gastrointestinal cancer risk. Cancer Causes Control. 2012;23(3):399–404.

    Article  PubMed  PubMed Central  Google Scholar 

  212. Fan X, Alekseyenko AV, Wu J, Peters BA, Jacobs EJ, Gapstur SM, et al. Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study. Gut. 2016;67:120. gutjnl-2016-312580

    Article  PubMed  Google Scholar 

  213. Cohen M. Antiretroviral agents prevent HIV transmission: where do we go from here? 30 years of HIV science: Imagine the future; May 23, 2013. Paris: Institut Pasteur; 2013. p. 44.

    Google Scholar 

  214. Ping L-H, Jabara CB, Rodrigo AG, Hudelson SE, Piwowar-Manning E, Wang L, et al. HIV-1 transmission during early antiretroviral therapy: evaluation of two HIV-1 transmission events in the HPTN 052 prevention study. PLoS One. 2013;8(9):e71557.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  215. Akinosho T. So much for a scare. AIDS finding continues the controversy but with little proof. THISWEEK. 1987 July 20, Sect. Nation. 1987

    Google Scholar 

  216. Williams CKO. HIV/AIDS pandemic in Africa: Chronicle of a missed opportunity. Annual meeting of the American Society of Clinical Oncology. p. Abstract: e22235. 2009

    Google Scholar 

  217. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005;2(11):e298.

    Article  PubMed  PubMed Central  Google Scholar 

  218. Fink AJ. A possible explanation for heterosexual male infection with AIDS. N Engl J Med. 1986;315(18):1167.

    CAS  PubMed  Google Scholar 

  219. Bongaarts J, Reining P, Way P, Conant F. The relationship between male circumcision and HIV infection in African populations. AIDS. 1989;3(6):373–8.

    Article  CAS  PubMed  Google Scholar 

  220. Drain PK, Halperin DT, Hughes JP, Klausner JD, Bailey RC. Male circumcision, religion, and infectious diseases: an ecologic analysis of 118 developing countries. BMC Infect Dis. 2006;6(1):1.

    Article  Google Scholar 

  221. Halperin DT, Bailey RC. Male circumcision and HIV infection: 10 years and counting. Lancet. 1999;354(9192):1813–5.

    Article  CAS  PubMed  Google Scholar 

  222. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007;369(9562):643–56.

    Article  PubMed  Google Scholar 

  223. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007;369(9562):657–66.

    Article  PubMed  Google Scholar 

  224. Saez-Cirion A. Natural and treatment induced control of HIV/SIV infections. 30 years of HIV science: imagine the future, Paris, 2013. p 50

    Google Scholar 

  225. Sáez-Cirión A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, Boufassa F, et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci. 2007;104(16):6776–81.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  226. Sáez-Cirión A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 2013;9(3):e1003211.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  227. Deeks S. Why curing HIV might be easier than assumed. 30 years of HIV science; Paris, 2013, p 49

    Google Scholar 

  228. Klein F, Mouquet H, Dosenovic P, Scheid JF, Scharf L, Nussenzweig MC. Antibodies in HIV-1 vaccine development and therapy. Science. 2013;341(6151):1199–204.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  229. Caskey M, Klein F, Nussenzweig MC. Broadly neutralizing antibodies for HIV-1 prevention or immunotherapy. N Engl J Med. 2016;375(21):2019–21.

    Article  CAS  PubMed  Google Scholar 

  230. Scheid JF, Mouquet H, Feldhahn N, Walker BD, Pereyra F, Cutrell E, et al. A method for identification of HIV gp140 binding memory B cells in human blood. J Immunol Methods. 2009;343(2):65–7.

    Article  CAS  PubMed  Google Scholar 

  231. Gautam R, Nishimura Y, Pegu A, Nason MC, Klein F, Gazumyan A, et al. A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature. 2016;533(7601):105–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  232. Mascola JR. The modern era of HIV-1 vaccine development. Science. 2015;349(6244):139–40.

    Article  CAS  PubMed  Google Scholar 

  233. McCoy LE, Weiss RA. Neutralizing antibodies to HIV-1 induced by immunization. J Exp Med. 2013;210(2):209–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  234. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343(2):78–85.

    Article  CAS  PubMed  Google Scholar 

  235. Julien JP, Lee PS, Wilson IA. Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA. Immunol Rev. 2012;250(1):180–98.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  236. Mascola JR, Haynes BF. HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol Rev. 2013;254(1):225–44.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  237. Sanders RW, Derking R, Cupo A, Julien J-P, Yasmeen A, de Val N, et al. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP. 664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 2013;9(9):e1003618.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  238. Karasavvas N, Billings E, Rao M, Williams C, Zolla-Pazner S, Bailer RT, et al. The Thai phase III HIV Type 1 vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retrovir. 2012;28(11):1444–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  239. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361(23):2209–20.

    Article  CAS  PubMed  Google Scholar 

  240. Vaccari M, Poonam P, Franchini G. Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV. Expert Rev Vaccines. 2010;9(9):997–1005.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  241. Fauci AS, Marston HD. Toward an HIV vaccine: a scientific journey. Science. 2015;349(6246):386–7.

    Article  CAS  PubMed  Google Scholar 

  242. P5. Renewed promise of an HIV Vaccine. In: Health U-NIo, editor. P5info@mailnih2015

    Google Scholar 

  243. Steinbrook R. HIV/AIDS in 2016 and Beyond. JAMA. 2016;316(11):1139–40.

    Article  PubMed  Google Scholar 

  244. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  245. Montaner JS, Lima VD, Harrigan PR, Lourenço L, Yip B, Nosyk B, et al. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the “HIV treatment as prevention” experience in a Canadian setting. PLoS One. 2014;9(2):e87872.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  246. UNAIDS. AIDS by the numbers. AIDS is not over but it can be. Geneva: UNAIDS; 2016. Available from: http://bit.ly/2ambo2P

    Google Scholar 

  247. UNAIDS. Prevention gap report: United National Programme on HIV/AIDS (UNAIDS). 2016. Available from: http://bit.ly/29Bjgji

  248. HIV/AIDS JUNPo, HIV/Aids JUNPo. 90–90-90: an ambitious treatment target to help end the AIDS epidemic. Geneva: UNAIDS. 2014

    Google Scholar 

  249. Holmes D. FDA paves the way for pre-exposure HIV prophylaxis. Lancet. 2012;380(9839):325.

    Article  PubMed  Google Scholar 

  250. Morin SF, Yamey G, Rutherford GW. HIV pre-exposure prophylaxis. BMJ-Brit Med J. 2012;345(7871):10.

    Google Scholar 

  251. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendation for a public health approach. Geneva: World Health Organization; 2016. Available from: http://bit.ly/2aDmypB

    Google Scholar 

  252. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  253. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  254. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  255. Anonymous. AIDS epidemic is over, down under. http://science.sciencemag.org/content/353/6296/202.full. 2016

  256. Adimora AA. Preventing HIV among women – a step forward, but much farther to go. Mass Medical Soc. 2016

    Google Scholar 

  257. McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53–60.

    Article  PubMed  PubMed Central  Google Scholar 

  258. Molina J-M, Capitant C, Spire B, Pialoux G, Chidiac C, Charreau I. On demand PrEP with oral TDF-FTC in MSM: results of the ANRS Ipergay trial. Conference on retroviruses and opportunistic infections. 2015

    Google Scholar 

  259. Volk JE, Marcus JL, Phengrasamy T, Blechinger D, Nguyen DP, Follansbee S, et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clin Infect Dis. 2015;61(10):1601–3.

    Article  PubMed  PubMed Central  Google Scholar 

  260. Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–18.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  261. Cottrell ML, Yang KH, Prince HM, Sykes C, White N, Malone S, et al. A translational pharmacology approach to predicting outcomes of preexposure prophylaxis against HIV in men and women using tenofovir disoproxil fumarate with or without emtricitabine. J Infect Dis. 2016;214(1):55–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  262. Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375:2121.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  263. Nel A, van Niekerk N, Kapiga S, Bekker L-G, Gama C, Gill K, et al. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016;375(22):2133–43.

    Article  CAS  PubMed  Google Scholar 

  264. Leichliter JS. Heterosexual anal sex: part of an expanding sexual repertoire? Sex Transm Dis 2008;35(11):910–1

    Article  PubMed  Google Scholar 

  265. Solanke TF, Osunkoya BO, CKO W, Agboola OO, editors. Cancer in Nigeria. Ibadan: Ibadan University Press, Publishing House; 1982.

    Google Scholar 

Download references

Statement of Consent

Human images, including those of minors, shown in this chapter were obtained in the course of a research project on Cancer in Nigeria [265] from July 1978 to July 1986. Christopher K. Williams, MD, who is the author of this book, led the research program. All images were obtained after verbal consent of patients, parents and/or guardians of minors.

Author information

Authors and Affiliations

  1. Hematology Oncology Consultancy, Port Angeles, WA, USA

    Christopher Kwesi O. Williams

Authors
  1. Christopher Kwesi O. Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Williams, C.K.O. (2019). Disease Presentation, Recognition and Prevention. In: Cancer and AIDS. Springer, Cham. https://doi.org/10.1007/978-3-319-99362-1_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-99362-1_1

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-99361-4

  • Online ISBN: 978-3-319-99362-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation